Compare TTRX & KPET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTRX | KPET |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.2M | 286.6M |
| IPO Year | N/A | 2026 |
| Metric | TTRX | KPET |
|---|---|---|
| Price | $9.58 | $9.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 99.8K | 59.5K |
| Earning Date | 05-31-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $9.95 |
| 52 Week High | $11.69 | $10.01 |
| Indicator | TTRX | KPET |
|---|---|---|
| Relative Strength Index (RSI) | 72.19 | N/A |
| Support Level | $4.40 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.01 | 0.00 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 63.17 | 0.00 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
KPET Ultra Paceline Corp is a Blank Check company. It is formed with the objective of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.